BiotechTube

Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-Resistant Prostatic Cancer

Conditions

Castration-Resistant Prostatic Cancer, Metastasis

Trial Timeline

Jul 3, 2025 → Feb 24, 2030

NCT ID
NCT06863272

About Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication

Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication is a phase 1/2 stage product being developed by Daiichi Sankyo for Castration-Resistant Prostatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06863272. Target conditions include Castration-Resistant Prostatic Cancer, Metastasis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06863272Phase 1/2Recruiting

Competing Products

20 competing products in Castration-Resistant Prostatic Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
EnzalutamideAstellas PharmaPhase 2
52
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
Crizotinib + EnzalutamideAstellas PharmaPhase 1
33
EnzalutamideAstellas PharmaPhase 2
52
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaApproved
85
enzalutamideAstellas PharmaPre-clinical
23
Enzalutamide + FlutamideAstellas PharmaPhase 2
52
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
23
EnzalutamideAstellas PharmaApproved
85
EnzalutamideAstellas PharmaPhase 2
52
MDV3100Astellas PharmaPre-clinical
23
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85